CAS: 19902-91-1; (S)-6-(2-(Benzo[d][1,3]Dioxol-5-yl)Ethyl)-4-Methoxy-5,6-Dihydro-2H-Pyran-2-One
该化合物是一种自然发生的化合物,主要见于植物物种* Mitragyna speciosa*, 通常称为Kratom.它属于类碱类,在结构上与同一工厂中发现的其他化合物有关.二氢甲基辛烷具有潜在的...
- 英文名称(S)-6-(2-(Benzo[d][1,3]Dioxol-5-yl)Ethyl)-4-Methoxy-5,6-Dihydro-2H-Pyran-2-One
- 中文名称二氢麻醉椒素
- IUPAC名称(S)-6-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-4-methoxy-5,6-dihydro-2H-pyran-2-one
- 其它别名6-(2-(1,3-Benzodioxol-5-yl)Ethyl)-5,6-Dihydro-4-Methoxy-2H-Pyran-2-On(S); 6-Dihydro-4-Methoxy-6-(3,4-(Methylenedioxy)Phenethyl)-(S)-2H-Pyran-2-On; 7,8-Dihydromethysticin; Dhm; Dihydromethylsticin; 7,8-Dihydromethylsticin; 5,6-Dihydro-4-Methoxy-6-[2-(1,3-Benzodioxol-5-yl)Ethyl]-2H-Pyran-2-One; 6-[2-(1,3-Benzodioxol-5-yl)Ethyl]-4-Methoxy-5,6-Dihydro-2H-Pyran-2-One
- CAS编号19902-91-1
- MFCD编号:MFCD00221731
- EINECS号:106-463-6
- FDA UNII编号:G9X3XK922J
- 分子式:C15H16O5分子量:276.29
- 产品CID: 1012576
- 产品分类分析化学 → 标准品 → 分析标准品
- 相似结构搜索
- InChIKey: RSIWXFIBHXYNFM-NSHDSACASA-N
- RSIWXFIBHXYNFM-NSHDSACASA-N
- 计算化学: 氢键受体数5.0氢键供体数*可旋转键数4.0
物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
(E)-6-[2-(benzo[d][1,3]dioxol-5-yl)vinyl]-4-methoxy-2H-pyran-2-one (+)-methysticin (+/-)-methysticin methanol7-benzo[1,3]dioxol-5-yl-3-methoxy-hepta-2,4-dienoic acid合成工艺路线路线简述
📜麻醉椒苦素置于钯体系中,用 四氢呋喃 用作溶剂,化学反应生成二氢麻醉椒素
参考文献:Kavalactone Compositions
标题:Kavalactone Compositions
摘要:这项发明涉及具有增进健康特性的组合物,更具体地涉及具有卡瓦内酮的组合物,以及这些组合物的用途和制备.
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2902600000-乙苯
2905122000-异丙醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-6677462-B2
优先权日:2001-08-06
标题:Asymmetric synthesis of kavalactones
发明人：CHEN SHOUJUN; SUN LIJUN; MCCLEARY JOEL
权利人:KAVA PHARMACEUTICALS INC
摘要:This invention relates to preparation of enantio-enriched compounds, and more particularly to enantio-enriched kavalactone compounds and derivatives thereof. The methods provide compounds that are useful as reagents, or building blocks, in the construction of other enantio-enriched compounds.
专利号:US-2019271015-A1
优先权日:2018-01-17
标题 :Enzymatic synthesis of kavalactones and flavokavains
专利号:US-10941429-B2
优先权日:2018-01-17
标 题:Enzymatic synthesis of kavalactones and flavokavains
专利号:CA-2456720-A1
优先权日:2001-08-06
标题 :Asymmetric synthesis of kavalactones
专利号:EP-1414463-A4
优先权日:2001-08-06
标题 :ASYMMETRIC SYNTHESIS OF KAVALACTONES
专利号:EP-1414463-A1
优先权日:2001-08-06
标题:Asymmetric synthesis of kavalactones
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1. Jamieson, D.D., and Duffield, P.H. The antinociceptive actions of kava components in mice. Clin. Exp. Pharmacol. Physiol. 17(7), 495-507 (1990). 2. Backhauβ, C., and Krieglstein, J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodent. Eur. J. Pharmacol. 215(2-3), 265-269 (1992). 3. Weiss, J., Sauer, A., Frank, A., et al. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab. Dispos. 33(11), 1580-1583 (2005).合成参考文献
参考文献:10.1078/0944711041495263
摘要:Zou L, Henderson GL, Harkey MR, Sakai Y, Li A. Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine. 2004;11(4):285–94. doi: 10.1078/0944711041495263.
参考文献:10.1016/j.cbi.2022.109883
摘要:Melchert PW, Qian Y, Zhang Q, Klee BO, Xing C, Markowitz JS. In vitro inhibition of carboxylesterase 1 by Kava (Piper methysticum) Kavalactones. Chemico-Biological Interactions. 2022 Apr;357():109883. doi: 10.1016/j.cbi.2022.109883.
参考文献:10.1016/s0021-9673(01)00979-7
摘要:Kubátová A, Miller DJ, Hawthorne SB. Comparison of subcritical water and organic solvents for extracting kava lactones from kava root. J Chromatogr A. 2001 Jul 20;923(1-2):187–94. doi: 10.1016/s0021-9673(01)00979-7.
摘要:Experientia., 26(283), 1970 []
摘要:Archives Internationales de Pharmacodynamie et de Therapie., 138(505), 1962 []
📝 需求与反馈
尽可能描述清楚需求与问题信息
